Immunomodulation as a neuroprotective and therapeutic strategy for Parkinson's disease

Katherine E. Olson, Howard Eliot Gendelman

Research output: Contribution to journalReview article

31 Citations (Scopus)

Abstract

While immune control is associated with nigrostriatal neuroprotection for Parkinson's disease, direct cause and effect relationships have not yet been realized, and modulating the immune system for therapeutic gain has been openly debated. Here, we review how innate and adaptive immunity affect disease pathobiology, and how each could be harnessed for treatment. The overarching idea is to employ immunopharmacologics as neuroprotective strategies for disease. The aim of the current work is to review disease-modifying treatments that are currently being developed as neuroprotective strategies for PD in experimental animal models and for human disease translation. The long-term goal of this research is to effectively harness the immune system to slow or prevent PD pathobiology.

Original languageEnglish (US)
Pages (from-to)87-95
Number of pages9
JournalCurrent Opinion in Pharmacology
Volume26
DOIs
StatePublished - Feb 1 2016

Fingerprint

Immunomodulation
Parkinson Disease
Immune System
Adaptive Immunity
Therapeutics
Innate Immunity
Animal Models
Research

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery

Cite this

Immunomodulation as a neuroprotective and therapeutic strategy for Parkinson's disease. / Olson, Katherine E.; Gendelman, Howard Eliot.

In: Current Opinion in Pharmacology, Vol. 26, 01.02.2016, p. 87-95.

Research output: Contribution to journalReview article

@article{7507f00d8bdc48af880c8c0734c62fb6,
title = "Immunomodulation as a neuroprotective and therapeutic strategy for Parkinson's disease",
abstract = "While immune control is associated with nigrostriatal neuroprotection for Parkinson's disease, direct cause and effect relationships have not yet been realized, and modulating the immune system for therapeutic gain has been openly debated. Here, we review how innate and adaptive immunity affect disease pathobiology, and how each could be harnessed for treatment. The overarching idea is to employ immunopharmacologics as neuroprotective strategies for disease. The aim of the current work is to review disease-modifying treatments that are currently being developed as neuroprotective strategies for PD in experimental animal models and for human disease translation. The long-term goal of this research is to effectively harness the immune system to slow or prevent PD pathobiology.",
author = "Olson, {Katherine E.} and Gendelman, {Howard Eliot}",
year = "2016",
month = "2",
day = "1",
doi = "10.1016/j.coph.2015.10.006",
language = "English (US)",
volume = "26",
pages = "87--95",
journal = "Current Opinion in Pharmacology",
issn = "1471-4892",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - Immunomodulation as a neuroprotective and therapeutic strategy for Parkinson's disease

AU - Olson, Katherine E.

AU - Gendelman, Howard Eliot

PY - 2016/2/1

Y1 - 2016/2/1

N2 - While immune control is associated with nigrostriatal neuroprotection for Parkinson's disease, direct cause and effect relationships have not yet been realized, and modulating the immune system for therapeutic gain has been openly debated. Here, we review how innate and adaptive immunity affect disease pathobiology, and how each could be harnessed for treatment. The overarching idea is to employ immunopharmacologics as neuroprotective strategies for disease. The aim of the current work is to review disease-modifying treatments that are currently being developed as neuroprotective strategies for PD in experimental animal models and for human disease translation. The long-term goal of this research is to effectively harness the immune system to slow or prevent PD pathobiology.

AB - While immune control is associated with nigrostriatal neuroprotection for Parkinson's disease, direct cause and effect relationships have not yet been realized, and modulating the immune system for therapeutic gain has been openly debated. Here, we review how innate and adaptive immunity affect disease pathobiology, and how each could be harnessed for treatment. The overarching idea is to employ immunopharmacologics as neuroprotective strategies for disease. The aim of the current work is to review disease-modifying treatments that are currently being developed as neuroprotective strategies for PD in experimental animal models and for human disease translation. The long-term goal of this research is to effectively harness the immune system to slow or prevent PD pathobiology.

UR - http://www.scopus.com/inward/record.url?scp=84946606692&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84946606692&partnerID=8YFLogxK

U2 - 10.1016/j.coph.2015.10.006

DO - 10.1016/j.coph.2015.10.006

M3 - Review article

VL - 26

SP - 87

EP - 95

JO - Current Opinion in Pharmacology

JF - Current Opinion in Pharmacology

SN - 1471-4892

ER -